Waqar Qureshi, MD
Gastroenterology · Houston, TXNPI 1497835813
Payments from drug & device makers
Across 294 payments — averaging $170.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$37K
- AbbVie$4K
- Conmed Corporation$1K
- Aries Pharmaceuticals, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$767
- Boston Scientific$709
- plus $5K from 28 others
What the payments were for
- Speaking & faculty fees$34,60069%
- Travel & lodging$2,1484%
- Food & beverage$13,49327%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 35 | $37,199 |
| AbbVie(2 entities) | 112 | $4,345 |
| Conmed Corporation | 24 | $1,322 |
| Aries Pharmaceuticals, Inc. | 4 | $1,133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $767 |
| Boston Scientific | 24 | $709 |
| Johnson & Johnson(3 entities) | 10 | $615 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $570 |
| GI Supply, Inc. | 1 | $507 |
| Olympus America Inc. | 5 | $445 |
| Medtronic | 3 | $422 |
| E.r. Squibb & Sons, L.L.C. | 2 | $249 |
| Steris Corporation | 1 | $206 |
| Alcresta Therapeutics, Inc. | 2 | $175 |
| Regeneron Healthcare Solutions, Inc. | 2 | $169 |
| Merck | 9 | $168 |
| Enterra Medical, Inc. | 1 | $152 |
| Fujifilm Healthcare Americas Corporation | 1 | $141 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Gilead | 1 | $124 |
| Ambu Inc. | 4 | $107 |
| Regeneron | 1 | $97 |
| Heartflow, Inc. | 3 | $88 |
| Ipsen Biopharmaceuticals, Inc | 1 | $80 |
| Lumendi LLC | 1 | $68 |
| Micro-tech Endoscopy USA, Inc. | 1 | $61 |
| Apollo Endosurgery US Inc | 2 | $37 |
| Ironwood Pharmaceuticals, Inc | 2 | $33 |
| Romark Laboratories, LC | 2 | $27 |
| Sanofi | 1 | $25 |
| Ardelyx, Inc. | 1 | $24 |
| QOL Medical, LLC | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$36,632
- ELEVIEW$1,100
- Creon$581
- CONMED BILIARY$562
- CONMED GENERATORS$506
- Rinvoq$344
- GATTEX$329
- CONMED HEMOSTASIS$277
- Tremfya$251
- XIFAXAN$233
- GI Genius$215
- TRUFREEZE$206
- ORISE$161
- RELIZORB$150
- NEXPOWDER$141
- FUJIFILM$141
- UROPASS II, 6.0 X 26 CM WO/GW$126
- ZENPEP$125
- ZEPOSIA$125
- Epclusa$124
How this compares
$50,240 in reported general payments places this provider in the 85th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 32 | $62,192 |
| LinzessLinaclotide | 36 | $23,123 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 114 | $7,225 |
| Dexlansoprazole DrDexlansoprazole | 15 | $5,888 |
| CholestyramineCholestyramine (With Sugar) | 15 | $3,427 |
| Omeprazole | 100 | $1,449 |
| Dicyclomine Hcl | 24 | $521 |
| Famotidine | 29 | $488 |
| Pantoprazole Sodium | 19 | $160 |
| Promethazine Hcl | 11 | $0 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $4,345 | $85,31568 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Houston
- Mazen NoureddinHouston$6.1M
- James MaherHouston$5.3M
- Uma MohanHouston$5M
- John VierlingHouston$2.8M
- Bincy AbrahamHouston$2.5M
- Jason HouHouston$2.3M
- Jignesh ShahHouston$1.7M
- Mouhamad Al-SabbaghHouston$1.6M
- Mohamed OthmanHouston$1.6M
- Harry OjeasHouston$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.